Author:
Million Matthieu,Lagier Jean-Christophe,Gautret Philippe,Colson Philippe,Fournier Pierre-Edouard,Amrane Sophie,Hocquart Marie,Mailhe Morgane,Esteves-Vieira Vera,Doudier Barbara,Aubry Camille,Correard Florian,Giraud-Gatineau Audrey,Roussel Yanis,Berenger Cyril,Cassir Nadim,Seng Piseth,Zandotti Christine,Dhiver Catherine,Ravaux Isabelle,Tomei Christelle,Eldin Carole,Tissot-Dupont Hervé,Honoré Stéphane,Stein Andreas,Jacquier Alexis,Deharo Jean-Claude,Chabrière Eric,Levasseur Anthony,Fenollar Florence,Rolain Jean-Marc,Obadia Yolande,Brouqui Philippe,Drancourt Michel,La Scola Bernard,Parola Philippe,Raoult Didier
Funder
Agence Nationale de la Recherche
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health
Reference28 articles.
1. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study;Zhou;Lancet,2020
2. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);Yao;Clin Infect Dis,2020
3. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro;Liu;Cell Discov,2020
4. Broad anti-coronaviral activity of FDA approved drugs against 1 SARS-CoV-2 in vitro and SARS-CoV in vivo;Weston;bioRxiv,2020
5. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication;Touret;bioRxiv,2020